Aminoskābes piemaisījumi, ko izmanto olbaltumvielu sintezēšanai
Produkta detaļa
| NO | Produkti | Cas nē | Galvenais kvalitātes indikators | |||
| Tīrība | Maks. piemaisījums | Kopējais šķīdinātāja atlikums | Mitrums | |||
| 1 | Fmoc-β-ala-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 2 | FMOC-D-Ala-d-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-Ala-D-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 4 | Fmoc-arg (pbf) -arg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 5 | Fmoc-β-ala-arg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 7 | FMOC-β-Ala-D-Arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 9 | Fmoc-β-ala-homoarg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 10 | Fmoc-asn (trt) -asn (trt) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-ala-asn (trt) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 12 | Fmoc-as (otbu) -asp (Otbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 13 | FMOC-β-Ala-Asp (Otbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 14 | Fmoc-cys (trt) -cys (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 15 | FMOC-β-Ala-Cys (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 16 | Fmoc-cys (ACM) -cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 19 | FMOC-β-Ala-Gln (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 21 | FMOC-β-Ala-Glu (OTBU) -OH.H2O | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 22 | FMOC-β-Ala-Gly-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 23 | Fmoc-his (TRT) -HIS (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 24 | Fmoc-β-ala-his (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 26 | FMOC-β-Ala-Ile-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 29 | FMOC-D-Leu-D-Leu-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 30 | FMOC-β-Ala-D-Leu-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 31 | Fmoc-lys (boc) -lys (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 32 | Fmoc-β-ala-lys (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 34 | Fmoc-β-ala-lys (alloc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-met-met-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 36 | FMOC-β-Ala-Met-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 37 | FMOC-ORN (BOC) -ORN (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 38 | FMOC-β-Ala-Orn (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 39 | Fmoc-phe-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 40 | Fmoc-β-ala-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 42 | FMOC-β-Ala-D-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 44 | FMOC-β-Ala-Pro-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 46 | FMOC-β-Ala-Ser (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 47 | Fmoc-ser (TRT) -ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 48 | FMOC-β-Ala-Ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tbu) -th (tbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 50 | Fmoc-β-ala-thr (tbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 51 | Fmoc-trp (boc) -trp (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-Ala-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 53 | Fmoc-d-trp (boc) -d-trp (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-Ala-D-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 56 | FMOC-β-Ala-tyr (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 57 | FMOC-D-TYR (ET) -D-tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (es) -tyr (es) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 60 | FMOC-β-Ala-tyr (ME) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 61 | Fmoc-valval-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-Ala-Val-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 64 | FMOC-β-Ala-D-Cit-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-ala-dab-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 66 | Fmoc- (3- (2-naftil) -d-ala) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-Ala-3- (2-naftil) -d-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-piridinil) -d-ala) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-Ala-3- (3-piridinils) -d-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 70 | Fmoc- (4-hlor-d-phe) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 71 | FMOC-β-Ala-4-hlor-d-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 72 | Fmoc- (d-4af (tbucbm)) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 73 | FMOC-β-Ala-D-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 74 | Fmoc-ifh (l-hor) -APH (l-hor) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 75 | Fmoc-β-ala-ifh (l-hor) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 76 | Fmoc-lys (IPR, BOC) -lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-Ala-lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 78 | FMOC-β-Ala-Aeea-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 80 | FMOC-β-Ala-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 82 | H-arg (pbf) -OH | 200115-86-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 84 | Hd-arg (pbf) -OH | 200116-81-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 86 | H-homoarg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 88 | HD-homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 91 | Fmoc-as-oh | 119062-05-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 92 | H-Asp (Otbu) -OH | 3057-74-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 95 | H-Cys (ACM) -OH.HCL | 28798-28-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 99 | H-Glu (OTBU) -OH.H2O | 2419-56-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 101 | H-his (trt) -OH | 35146-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 104 | H-lys (boc) -OH | 2418-95-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 105 | H-lys (alloc) -OH | 6298/3/9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 106 | FMOC-EROR-OH.HCL | 201046-57-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 107 | H-ORN (BOC) -OH | 13650-49-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 109 | H-ser (tbu) -OH | 18822-58-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 110 | H-Ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 111 | FMOC-THR-OH.H2O | 73731-37-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 112 | H-th (tbu) -OH | 4378-13-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 114 | H-trp (boc) -OH | 146645-63-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 117 | FMOC-tyr-oh | 92954-90-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 118 | H-tyr (tbu) -OH | 18822-59-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 119 | FMOC-D-TYR-OH | 112883-29-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 120 | HD-tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 121 | H-tyr (es) -OH.HCL | 67423-44-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 124 | Fmoc-lys (ipr) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 125 | H-lys (Ipr, boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
Pret
Kompensācija
Gentolex nodrošina lieliskas kvalitātes produktus, ja klients paaugstina produktu kvalitāti nepieciešamajā laika posmā ar pietiekamiem pierādījumiem, mēs sniegsim nepieciešamo analīzi un novērtēšanu, lai izraisītu kompensāciju procedūras.
Ražošana
Farmaceitisko produktu spējas sasniedza tonnu pakāpi, ķīmisko produktu spējas sasniedz 100tonus+ pakāpi, iespējas ir labi aprīkotas, lai apkalpotu klientus visā pasaulē.
Pētniecība un attīstība
Katru gadu R&D komanda ir izveidojusi plānu, lai izstrādātu dažādus jaunus produktus, kad mērķi ir izvirzīti, katram komandas loceklim būs jāturpina atbildība par KPI atbildību un stimulēšanas politiku.
